Home > About GAMMAGARD LIQUID > What to Expect

GAMMAGARD LIQUID for IV Administration

With GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10%, you and your doctor can decide whether intravenous (IV) or subcutaneous (SubQ) administration is best for you. This decision will shape your infusion experience, including where and how often you receive treatment and whether you, your caregiver, or your healthcare professional administers the infusion.1

IVIG Treatment

  • GAMMAGARD LIQUID for IV administration is administered by a healthcare professional at a single infusion site into a vein1
  • Since it is infused into a vein, the antibodies immediately begin circulating in your bloodstream1,2
  • IV treatment can be given at a hospital or clinic or at home, every 3 or 4 weeks1
  • Your dose and infusion rate will be prescribed based on your clinical response and tolerability1

What to Expect With IV Treatment

Before the infusion:

  • Bring a book, music player, or other materials to keep yourself occupied during the infusion
  • Many hospitals will have you sign a consent form to ensure you are informed of the potential risks of your treatment3
  • The nurse will place the IV catheter in the vein1

During the infusion:

  • Relax and sit comfortably3
  • Let the nurse know if you feel uncomfortable at any time

After the infusion:

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc. 2. Blaese RM, Bonilla FA, Stiehm ER, Younger ME, eds. Patient & Family Handbook for Primary Immunodeficiency Diseases. 5th ed. Towson, MD: Immune Deficiency Foundation; 2013. 3. Younger MEM, ed. IDF Guide for Nurses: Immunoglobulin Therapy for Primary Immunodeficiency Diseases. 4th ed. Towson, MD: Immune Deficiency Foundation; 2016.

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.


Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.

© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.


What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.